LifeTime and improving European healthcare through cell-based interceptive medicine

, Nikolaus Rajewsky (Lead / Corresponding author), Geneviève Almouzni (Lead / Corresponding author), Stanislaw A. Gorski (Lead / Corresponding author), Stein Aerts, Ido Amit, Michela G. Bertero, Christoph Bock, Annelien L. Bredenoord, Giacomo Cavalli, Susanna Chiocca, Hans Clevers, Bart De Strooper, Angelika Eggert, Jan Ellenberg, Xosé M. Fernández, Marek Figlerowicz, Susan M. Gasser, Norbert Hubner, Jørgen KjemsJürgen A. Knoblich, Grietje Krabbe, Peter Lichter, Sten Linnarsson, Jean Christophe Marine, John Marioni, Marc A. Marti-Renom, Mihai G. Netea, Dörthe Nickel, Marcelo Nollmann, Halina R. Novak, Helen Parkinson, Stefano Piccolo, Inês Pinheiro, Ana Pombo, Christian Popp, Wolf Reik, Sergio Roman-Roman, Philip Rosenstiel, Joachim L. Schultze, Oliver Stegle, Amos Tanay, Giuseppe Testa, Dimitris Thanos, Fabian J. Theis, Maria Elena Torres-Padilla, Alfonso Valencia, Céline Vallot, Alexander van Oudenaarden, Marie Vidal, Thierry Voet

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

LifeTime aims to track, understand and target human cells during the onset and progression of complex diseases and their response to therapy at single-cell resolution. This mission will be implemented through the development and integration of single-cell multi-omics and imaging, artificial intelligence and patient-derived experimental disease models during progression from health to disease. Analysis of such large molecular and clinical datasets will discover molecular mechanisms, create predictive computational models of disease progression, and reveal new drug targets and therapies. Timely detection and interception of disease embedded in an ethical and patient-centered vision will be achieved through interactions across academia, hospitals, patient-associations, health data management systems and industry. Applying this strategy to key medical challenges in cancer, neurological, infectious, chronic inflammatory and cardiovascular diseases at the single-cell level will usher in cell-based interceptive medicine in Europe over the next decade.

Original languageEnglish
JournalNature
Early online date7 Sep 2020
DOIs
Publication statusE-pub ahead of print - 7 Sep 2020

Fingerprint Dive into the research topics of 'LifeTime and improving European healthcare through cell-based interceptive medicine'. Together they form a unique fingerprint.

  • Cite this

    , Rajewsky, N., Almouzni, G., Gorski, S. A., Aerts, S., Amit, I., Bertero, M. G., Bock, C., Bredenoord, A. L., Cavalli, G., Chiocca, S., Clevers, H., De Strooper, B., Eggert, A., Ellenberg, J., Fernández, X. M., Figlerowicz, M., Gasser, S. M., Hubner, N., ... Voet, T. (2020). LifeTime and improving European healthcare through cell-based interceptive medicine. Nature. https://doi.org/10.1038/s41586-020-2715-9